Background: In drug development, it is important to have an understanding of the full spectrum of co-morbidities to be expected in the group of patients with the disease of interest. It is usually a challenge to identify the less common events associated with the target disease, even if these events are severe. The purpose of this study is to identify co-morbidities associated with rheumatoid arthritis (RA) as compared with a control group, using a large health care database. Methods: Marketscan US claims database was used for this retrospective cohort study. Selected were records of persons aged at least 16 Y with at least two claims for RA, and with active insurance status on June 30,2007. The control group had at least two claims for eczema/dermatitis. Controls were matched by age, gender and insurance status (Medicare or not). All co-morbidities with an ICD9 diagnostic code were identified in the RA and control groups, during a one-year window. Relative risks (RRs) were calculated. Diagnoses were rank-ordered by magnitude of RR. Codes covering RA and arthropathy were excluded. In order to get stable estimates, rank-ordering was performed for diagnoses occurring in at least 20 persons in the control group.
Background
In post-marketing surveillance, often questions arise about characteristics of the patient group for which a drug is indicated, such as the age distribution and comorbidities to be expected [1, 2] . Therapeutic risk management involves an understanding of characteristics specific to a group of patients for whom a drug will be prescribed. Often, some safety issues of a new product are predictable; however after market introduction in practice often adverse events are reported that were not foreseen [3, 4] . A description of all co-morbidities seen in the target population would help better understand the patient population and thus, provide some context for new safety issues.
Referring to Risk Management Plans (RMPs) submitted to regulatory authorities, a guide on pharmacovigilance published by the Medicines and Healthcare products Regulatory Agency in the UK comments that some RMPs tend to focus on what is already known rather than identifying the areas in which information is lacking [5] . It was also noted that the relevance of the epidemiology of the disease to the target indication is often not sufficiently considered.
To help address these issues, data on large groups from the general population are needed. Increasingly in the past years, health-care databases have become available that enable the study of large numbers of patients with follow-up data. The US Food and Drug Administration Amendment Act of 2007 (FDAAA) called for the establishment, under the auspices of an independent foundation, of a set of databases of health insurance claims data for 100 million people by 2012 [6, 7] . Thus, data on sufficient numbers of patients are becoming more available to better understand the co-morbidities in groups or subgroups of patients with a target disease.
Listing co-morbidities, rank-ordered by prevalence, will show various conditions associated with the disease of interest; these associations may be either known, or not yet established. Additionally, such data on a patient group will reflect the target group for a product. The target indication is often restricted by criteria relating to severity of disease or by treatments given earlier. While healthcare databases usually do not have sufficient data on stage or severity of a specific disease, prescribed medication is usually well covered. A subgroup within a healthcare database can be selected, identified by disease codes and restricted by criteria on medication. Information gathered on age/sex profile, co-morbidities and comedication of such a group should help to describe disease epidemiology specific for a target indication.
Rheumatoid arthritis is a chronic condition characterized by inflammation and modulation of immunity, affecting many organs apart from the loco-motor system. Various studies have described associations of RA with selected morbidities such as infectious conditions [8] [9] [10] and cardiovascular disease [11] [12] [13] [14] . Because of this potential association with many conditions, it was chosen as the target condition to describe unselected co-morbidity in a data-driven way. The objective was to quantify a large number of co-morbidities associated with RA, as compared to a control group. Associations found should not be assumed to be causal; however they can provide a base for further analyses and for hypothesis testing in different data sets. [15] ; Medicaid covers individuals and families with low income and resources. Elderly are well represented, through the inclusion of groups covered by Medicare, the US social insurance program for people who are aged 65 years and over.
Methods

Thomson
MarketScan research databases meet or exceed requirements of the US Health Insurance Portability and Accountability Act (HIPAA) of 1996. The MarketScan databases underwent a statistical analysis by a third party confirming that HIPAA requirements for fully deidentified data sets were met. Thus, data use met HIPAA criteria for anonymous and aggregate research analysis and reporting of data derived from clinical records not requiring specific patient consent or ethical approval.
Cases were defined as persons with at least two claims for RA [codes ICD 9: 714.0*, 714.1*, 714.2*, and 714.3*.] that were non-diagnostic (i.e. not blood, lab, radiological claims) with active insurance status on June 30, 2007. At least one diagnosis of RA had to be before July 1 2006 and the index date was defined as the earliest claim containing the diagnosis. The control group was patients who had at least two claims for eczema/dermatitis [codes ICD 9: 690.*, 691.*,692.*] with the same criteria as the cases for insurance status and timing of the claims. Controls were matched 1:1 to the cases, by age, gender and health plan [Medicare or not] using propensity scores.
Propensity matching was done using a logistic regression model on dependent variable RA = 0,1 where 1 = in RA cohort and with explanatory variables: age, sex, and health plan (Medicare or not). The propensity score is the probability of being in the RA cohort. Then, one control was selected for each case based on a best match algorithm, using 8 digits of the probability value, then 7 digits, etc. [16] Each control was used only once. SAS version 8.2 was used for all analyses.
All co-morbidities with a level 5 -i.e. the most detailed -ICD9 (diagnostic) code were identified in the case and control groups in the one-year window from July 1, 2006 through June 30, 2007. A one-year period prevalence was calculated for each co-morbidity for both case and control groups. Occurrence of each comorbidity was counted only once for each patient.
Also, a set of relative risks (RR) was calculated for patients aged at least 16 years old as of RA index date, by dividing the one-year period prevalence of each comorbidity in the RA group with the corresponding prevalence in the controls. Thus, the RR represents here a ratio of one-year prevalences. After this, the various comorbidities were rank-ordered by magnitude of RR; 95% confidence intervals were added.
ICD9 4] . In order to obtain stable estimates, rankordering was done for non-rare diagnoses (occurring in at least 20 persons in control group).
Results
Records for 62,681 persons with RA were selected (all ages). Mean age was 59.0 Y, with 73.8% female, 35% Medicare-covered. A total of 6,897 different ICD9 diagnostic codes were recorded in this group, of which 2,220 occurred in 20 or more persons with RA.
The most prevalent co-morbidities in the cohort with RA are listed in Table 1 . At the more detailed level of the ICD9 classification (level 5), the most commonly registered co-morbidities were hypertension not otherwise specified (NOS) (20.4%), benign hypertension (19.9%), chest pain NOS (13.9%), and hyperlipidemia not elsewhere classified (NEC)/NOS (13.9%).
A total of 61,591 persons with RA were aged at least 16 years and subsequently matched with the control group. Demographic distribution for RA cases is shown in Figure 1 . The demographic distribution of the controls was identical. Co-morbidities strongly associated with RA in the case group compared to controls are shown in Table 2 and Figure 2 . A full set of co-morbidities is provided in additional File 1: Rank-ordered relative risks of co-morbidities in patients with rheumatoid arthritis.
Additional file 2 shows top 30 of relative risks as well as odds ratios of co-morbidities in patients with RA; comparator group had dermatitis/eczema diagnosis Additional file 3 shows same analysis as additional file 2, however with a different (random) comparator group.
Strong associations with RA (RR > 3) were found for psoriatic arthropathy, adverse effect to medicine/biological, reaction to internal joint prosthesis, unspecified adverse effect, osteoporosis, idiopathic fibrosing alveolitis, osteomyelitis, immune deficiency, elevated sedimentation rate, tuberculin test reaction, anemia and Cushing syndrome [Table 2, Figure 2 ]. As described in the Methods section, a set of ICD codes covering conditions of the loco-motor system was excluded from the analysis. All RRs in Table 2 were statistically significant. The full set of co-morbidities as shown in additional File 1 includes many with a RR < 1, i.e. associated with the control group. Many of these are skin conditions.
Discussion
Data on a large number of patients (>60,000) with a diagnosis of rheumatoid arthritis were available, with a large number (>6,000) of different ICD9 diagnostic codes. Most prevalent co-morbidities were in the cardiovascular area: hypertension, chest pain and hyperlipidemia. The rank-ordering of relative risks shows a variety of conditions to be associated with RA. Some of these have been reported previously such as fibrosing alveolitis [17, 18] and acute stomach ulcer [19, 20] ; it also shows a strong and statistically significant association with osteomyelitis. Published studies on even relatively large cohorts of RA patients typically show only a few cases of this rare but severe infection. [21] [22] [23] . Also, of note, is the strong association found with 'adverse effect to medication'; this is an ICD-9 category with no information on the nature of the reaction or the product imputed. RR for osteoporosis is markedly increased, also for various fractures; this is in line with the findings of Van Staa et al based on the General Practice Research Database in the UK [24] . Osteoporosis is likely a direct consequence of RA, decreased physical activity and treatments with corticosteroids [25] . The association of RA with psoriatic arthropathy may be a consequence of similarities of signs of these conditions in their early stages where follow-up of patients would lead to a change of diagnosis. Psoriatic arthropathy is in the ICD category of skin conditions; hence it was included in Table 2 . The many diagnostic codes that are part of ICD categories that cover arthritis and other conditions of the locomotor system have been excluded as these were not the focus of the co-morbidity analysis. However these are included in additional File 1: Rankordered relative risks of co-morbidities in patients with rheumatoid arthritis. All RRs shown in Table 2 are statistically significant with lower boundaries of the 95% confidence interval above 1. This is a result of conditions being both strongly associated with RA and not too rare (at least 20 cases in control group).
It should be stressed that some less common events may be highly relevant from a drug safety perspective. A data set covering information on patients with RA or any other condition may indeed be used for analysis of any event of interest, irrespective of its rate of occurrence.
The control group included a group of patients with a non-systemic chronic condition (eczema/dermatitis) occurring in a broad age range, but with no direct relation to RA.
The choice of a control group of patients with another chronic condition should help to control for bias in detecting co-morbidities as both groups have exposure to health care. It should be noted however that some diagnoses that are relatively common both in the general population and in the RA population such as various skin conditions have a RR under 1 due to an association with the control group. For example 'pruritic disorders NOS' had a RR of 0.40.
Various control groups may be selected, depending on the types of outcomes of interest. For example, some diagnoses are typically made in the setting of out-patient clinics, other ones during hospital stays. The choice of control groups should take these differences into account.
As with any data source, claims data have limitations which are due both to the nature of administrative claims for payment purposes and convenience samples as opposed to random samples of the population. As such, they may contain biases or fail to generalize well to other populations. Clinical knowledge about comorbidities of RA or eczema/dermatitis is likely to drive the conditions that clinicians test for and deem worth recording. Information on important aspects such as smoking behaviour and ethnicity is missing. Associations found should not be considered to be causal. Rank- ordering of RRs of diagnostic codes is a tool to quickly identify characteristics specific to patients with a condition of interest. This can be applied to various subgroups of patients with the condition selected such as patients treated with different pharmaceutical products of interest. Comparisons of such groups can show whether products are prescribed to patients with different co-morbidity patterns prior to treatment. Understanding such selective prescribing can help in the interpretation of reported adverse effects of new products, as a part of good risk management practice.
Conclusions
Rank-ordering of relative risks of diagnostic codes is a tool to quickly identify co-morbidities specific to a patient group of interest, in this case patients with rheumatoid arthritis. Conditions with a strong (RR > 3), statistically significant association with RA included osteomyelitis; the large cohort of RA patients (> 60,000) covered makes it possible to quantify risk for this and other uncommon co-morbiditities.
Additional material
Additional file 1: Rank-ordered Relative Risks of co-morbidities in patients with rheumatoid arthritis. RR as compared with control group (N = 61,591 for each group). 16 years and older. Arthritis/RArelated codes included. Conditions included for which there were at least 20 controls. Number of RA cases in table may be less than 20 if RR < 1, i.e. if fewer cases than controls have condition. Shown: ICD9 codes, description of co-morbidity, number of persons in group with RA, percentage of group with RA, Relative Risk. NOS: Not otherwise specified NEC: Not elsewhere classified.
Additional file 2: Top 30 Relative risks and Odds ratios in patients with rheumatoid arthritis. Comparator group with Dermatitis/ Eczema diagnosis (N = 61,591 for each group). 16 years and older. RR + OR with 95% confidence intervals. Conditions included for which there were at least 20 controls. Shown: ICD9 codes, description of co-morbidity, numbers of persons with co-morbidity in RA and control groups, Relative Risk, numbers of persons without co-morbidity in RA and control groups, Odds Ratio. 95% Confidence Intervals.
Additional file 3: Top 30 Relative risks and Odds ratios in patients with rheumatoid arthritis. Comparator random group (N = 61,591 for each group). 16 years and older RR + OR with 95% confidence intervals. Conditions included for which there were at least 20 controls. Shown: ICD9 codes, description of co-morbidity, numbers of persons with co-morbidity in RA and control groups, Relative Risk, numbers of persons without co-morbidity in RA and control groups, Odds Ratio. 95% Confidence Intervals.
